A series of per-O-benzoylated 5-b-D-glucopyranosyl-2-substituted-1,3,4-oxadiazoles was prepared by acylation of the corresponding 5-(b-D-glucopyranosyl)tetrazole. As an alternative, oxidation of 2,6-anhydro-aldose benzoylhydrazones by iodobenzene I,I-diacetate afforded the same oxadiazoles. 1,3-Dipolar cycloaddition of nitrile oxides to per-O-benzoylated b-D-glucopyranosyl cyanide gave the corresponding 5-b-D-glucopyranosyl-3-substituted-1,2,4-oxadiazoles. The O-benzoyl protecting groups were removed by base-catalyzed transesterification. The 1,3,4-oxadiazoles were practically inefficient as inhibitors of rabbit muscle glycogen phosphorylase b while the 1,2,4-oxadiazoles displayed inhibitory activities in the micromolar range. The best inhibitors were the 5-b-D-glucopyranosyl-3-(4-methylphenyl-and -2-naphthyl)-1,2,4-oxadiazoles (K i = 8.8 and 11.6 lM, respectively). A detailed analysis of the structureactivity relationships is presented.
Introduction
The worldwide increasing prevalence of Type 2 Diabetes Mellitus (T2DM) has become a major health problem for most of the world's population. 1 Several oral hypoglycemic agents [2] [3] [4] (sulfonylureas,
biguanides, thiazolidinediones, a-glucosidase inhibitors 5 ) are now being used to help diabetic patients to reduce hyperglycemia. Such symptomatic treatments are intended to reach normal physiological blood glucose levels. However, they have several undesirable side effects and may also cause hypoglycemia. 6 These drugs are inadequate for 30-40% of patients. 7 Due to the appearance and spreading of T2DM among young adults as well as children, the coming decades must face severe economic and health service burdens. [8] [9] [10] Fuelled by all these facts, several new therapeutic possibilities are under investigation. [11] [12] [13] Among them, liver glycogen phosphory-60 lase (GP), an enzyme responsible for the phosphorylative degradation of glycogen, has been shown to be a target for the treatment of T2DM. 14, 15 Since GP appears as the rate limiting enzyme of glycogen degradation, its inhibition may offer a means for regulating blood sugar levels. A number of inhibitors have been discovered and designed in recent years targeting the different binding sites identified for GP. 20, 25 Among these inhibitors, a large array of glucose derivatives binds at the catalytic site of the enzyme. 20, 25 Among the first efficient glucose analogs were the N-acyl-glucopyranosylamines, for 70 example, 1a,b,h,i (Chart 1), and further inhibitor design led to the discovery of more potent N-acyl-N 0 -b-D-glucopyranosyl-ureas like 2a,b,h,i. As another class of efficient molecules, we developed several inhibitors having C-glucosyl heterocyclic structural elements such as tetrazole 3, benzimidazole 4, benzothiazole 5, 1,3,4-oxadiazole 21, 22 6a and 1,2,4-oxadiazoles 7a,b,i and 8b, 23, 24 as well as hydroquinone derivatives. 26 Several of these compounds displayed an inhibition against rabbit muscle glycogen phosphorylase b (RMGPb) in the low micromolar range.
In Since the preliminary results obtained with the two other isomeric oxadiazoles (6a and 8b) were encouraging with respect to GP inhibition, we planned a broader study of structure-activity relationships of C-glucosylated oxadiazoles. We present herein the synthesis of 5-(b-D-glycopyranosyl) derivatives of 2-substituted-1,3,4-and 3-substituted-1,2,4-oxadiazoles with a diverse set of aromatic residues as well as a detailed comparative analysis of structure-activity relationships of the different isomeric oxadiazole derivatives.
Results and discussion
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The nature of the aryl substituent of the oxadiazole ring is influencing the binding to the enzyme's catalytic site. We therefore prepared a series of molecules incorporating either basic (p-amino), acidic (p-hydroxy) or neutral (p-methyl, p-methoxy, p-nitro) substituents on the phenyl residues as well as larger aromatic moieties (1-and 2-naphthyl). The syntheses of the target oxadiazoles were achieved using per-O-benzoylated b-D-glucopyranosyl cyanide 9 as a common starting material. 
Q3
a Because of a $80% homology between the liver and muscle isoforms of GP, it is a general practice to use the more readily available RMGP for kinetic studies.
b Numbering of molecules is based on the complete set of molecules presented in Table 1 . 24 1,3-Dipolar cycloaddition of nitrile oxides to nitriles provides an efficient and short route to diversely substituted 1,2,4-oxadiazoles.
U N C O R R E C T E D P R O O F
Synthesis of 3-aryl-5-(b-D-glucopyranosyl)-1,2,4-oxadiazoles
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The nitrile oxides can be easily obtained from the corresponding hydroximoyl chloride precursors 16 which will undergo a dehydrohalogenation in the presence of a base. The addition of the base must occur in the presence of the dipolarophile in order to avoid the formation of nitrile oxide dimers. Hydroximoyl chlorides are therefore synthesized in a two-step process from the corresponding aldehydes by a reaction with hydroxylamine hydrochloride to afford the oxime intermediates which are then treated with N-chlorosuccinimide to afford the desired hydroximoyl chlorides 16 (Scheme 3). The purification of the oxime intermediates was required in order 150 to obtain reproducible results and also to reach high purity of the hydroximoyl chlorides since their purification by standard column chromatography was usually not successful due to their poor stability. Glucosyl cyanide 9 was then reacted with the hydroximoyl chlorides 16 in the presence of Et 3 N at low concentration in refluxing toluene to afford the desired 1,2,4-oxadiazoles 17. The addition of the base was achieved at a slow rate with a syringe pump. Subsequent transesterification of the benzoate esters under Zemplén conditions afforded the expected 1,2,4-oxadiazoles 8 in high yields. A small proportion (4-8%) of 1,2-endo-glycals 18b-e,i were also 160 isolated while their formation could not be detected for other aryl substituents. We previously observed that a substituent at the 5-position of the 1,2,4-oxadiazole ring possessing an acid-labile a-proton would be susceptible of deprotonation or even b-elimination if a leaving group is present at the b-position. 22 Similar observations were made with other ester protected carbohydrate derivatives such as glycosyl cyanides 29, [38] [39] [40] C-glycosyl thiadiazole 41 or benzothiazole. 29 Interestingly, this elimination was not observed in the 1,3,4-oxadiazole series 11. Finally, the reduction of the p-nitrophenyl-substituted derivative 8e to the corresponding p-aminophe-170 nyl oxadiazole 8f was achieved under standard hydrogenation conditions (Pd-C 10%, H 2 , 1 atm). The p-benzyloxy-phenyl derivative 8j was initially prepared in order to obtain the p-hydroxy-phenyl substituted oxadiazole 8g through hydrogenolysis of the benzyl group. But, since the direct 
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access to 8g could be achieved using the general synthetic route from a-chloroarylaldoxime 16g, we therefore considered the p-benzyloxy-phenyl derivative 8j as an additional candidate for the inhibition of GP. The benzo [1, 3] dioxol-5-yl substituted 1,2,4-oxadiazole 8k was synthesized in order to evaluate its inhibition towards the enzyme since the hydrophobic aromatic residue could interact with the b-channel of GP and also since this aromatic residue can be found as a pharmacophore in a series of natural products and synthetic drugs.
Enzymatic evaluation of oxadiazoles as GP inhibitors
The kinetic parameters of the synthesized molecules were then determined according to our previously described enzymatic protocol. 26 We compared the inhibition properties of C-glucosylated Table 1 ). In the N-acyl-N 0 -b-D-glucopyranosyl urea series 2, an overall equivalent inhibition in the micromolar range was observed for the benzoyl analogs (2b-g R = (p-substituted)phenyl). The 1-naphthoyl derivative 2h was a somewhat worse inhibitor of GP. A simple change to the 2-naphthoyl moiety (2i) remarkably improved the inhibition compared to 2h (43-fold increase) and more moderately in comparison to the benzoyl derivative 2b (13-fold increase). The 2-naphthoyl derivative 2i was the first glucose-based inhibitor with sub-micromolar activity against GP. In 200 the series N-acyl-b-D-glucopyranosylamines 1, a similar observation could be made since the 2-naphthoyl derivative 1i was the best inhibitor, found much more effective (44-fold) than 1h, with a regioisomeric 1-naphthoyl residue. Other members of this family displayed usually weak inhibition with the exception of the acetyl derivative 1a with a K i value of 32 lM. The methyl substituted oxadiazoles 6a and 7a and acetyl urea 2a showed poor (6a, 2a) or no detectable (7a) inhibition.
The 3-C-glucosylated 1,2,4-oxadiazoles 7 with a large series of aromatic substituents displayed the same inhibition pattern with 210 the 2-naphthyl derivative 7i as the best inhibitor in the series. The phenyl substituted oxadiazole 7b was a poor inhibitor and the p-nitrophenyl derivative 7e displayed the worst inhibition in the series. This detrimental effect exerted by the nitro group was not observed in the acyl urea series (compare 7e and 2e). Nevertheless, the biological activity of these 3-C-glucosylated Table 1 Inhibition (K i or *IC 50 (lM)) of rabbit muscle glycogen phosphorylase b by 
1,2,4-oxadiazoles 7 was always weaker than the corresponding N-acyl-N 0 -b-D-glucopyranosyl ureas 2. The 5-C-glucosylated 1,2,4-oxadiazoles 8 are generally better inhibitors than the corresponding 3-C-glucosylated counterparts 220 7 and followed a similar trend with the 2-naphthyl derivative 8i being among the best (displaying a value very close to the strongest inhibitor 8c) and the p-nitrophenyl 8e the worst in the series. The weak inhibition observed for the p-benzyloxy-phenyl derivative 8j might be attributed to the steric hindrance of the benzyl moiety in comparison to the naphthyl residue and also to the rotation around the methylene benzylic group creating an entropy loss for the binding process.
Very surprisingly, the 1,3,4-oxadiazoles 6 with a substituent larger than methyl did not display any meaningful inhibition 230 against RMGPb. To explain this unexpected result, we propose to consider the binding peculiarities of these molecules to the active site of GP as revealed by X-ray crystallography. Because of the lack of binding of the 1,3,4-oxadiazoles one has to go back to the structure of the enzyme-inhibitor complex obtained with the methylated analogue 6a, while an X-ray structure is available for the enzyme-complex of the 2-naphthyl substituted 8i.
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There are no direct H-bonds between the heterocycle of 6a and the protein, however, an extensive H-bond network involving nitrogen atoms N-3 and N-4 exists with the participation of water 240 molecules. 22 As a result, 6a binds in the orientation shown in Figure 1a . The compound can be accommodated at the catalytic site with essentially no disturbance of the protein structure. The relatively small methyl group makes 6 van der Waals interactions while the b-channel remains unoccupied. Similarly, no direct H-bonds could be observed between the heterocycle of 5-glucosyl-1,2,4-oxadiazole 8i and the protein. 25 The nitrogen atom N-4 takes part in a H-bond network mediated by water molecules. Due to the isomeric constitution of the heterocyclic part of this molecule as compared to 6a, the 3-substituent is 250 in a favorable position to make interactions with residues surrounding the b-channel. The aromatic moiety makes 11 van der Waals contacts in the b-channel for the 2-naphthyl derivative 8i. These interactions result in a strong binding with the orientation of 8i represented by Figure 1d . For the isomeric oxadiazoles 7 (Fig. 1c) , a similar interaction pattern and orientation can be postulated. In the case of the 1,3,4-oxadiazole series with large aromatic substituents (6) , interactions in the b-channel would require a rotameric orientation of the heterocycle as shown in Figure 1b . However, this conformation would ultimately result in a loss of 260 participation of N-3 and N-4 in the H-bond network. In the other orientation (like in Fig. 1a) , the accommodation of large substituents in the vicinity of the catalytic site would most probably significantly disturb the protein structure. These factors together prevent compounds 6 from strong binding to GP.
Conclusion
The synthesis of three series of C-glycosylated oxadiazoles could be achieved Enzyme kinetic evaluation of these inhibitors showed that the nature of the oxadiazole ring attached to C-1 of glucopyranose is strongly influencing the inhibitory activity towards RMGPb. While 280 the 1,3,4-oxadiazoles proved practically inactive, the 1,2,4-oxadiazole series displayed inhibition in the micromolar range with the 5-glucosylated derivatives being superior to their 3-glucosylated regioisomers. The nature of the p-substituent of the phenyl moiety exhibited a similar influence on the inhibition of GP in each series. In addition, the size and orientation of the aromatic substituent of the oxadiazole strongly modulated the activity. The 2-naphthyl derivatives in both 1,2,4-oxadiazole series were among the best inhibitors. A possible explanation was proposed to understand the differences in the inhibitory strengths of the isomeric oxadiazoles. 
was added. The reaction mixture was stirred at 90°C for 1 h. It was then cooled to rt, water was added, and extracted with CH 2 Cl 2 (3 Â 40 mL). The combined organic phase was washed with saturated aqueous NaHCO 3 solution and water. The organic phase was dried (MgSO 4 ), concentrated under diminished pressure and the crude product was purified by column chromatography (hexane-EtOAc 3:1) and then crystallized from EtOH. Method B: Perbenzoylated glucopyranosyl-tetrazole 10 was dis-330 solved in abs. toluene (100 mg/mL) then acid chloride (1.2-2 equiv) was added in one portion. The mixture was refluxed and monitored by TLC. After disappearance of the starting material the solvent was removed under diminished pressure, the residue was purified by column chromatography if necessary and crystallized from EtOH. Method C: An anhydro-aldose benzoylhydrazone (12 or 14, 0.25 mmol) was dissolved in CH 2 Cl 2 (2.4 mL) and PIDA (159 mg, 0.50 mmol) was added. The reaction mixture was stirred at rt. When the reaction was complete (TLC: EtOAc/hexane, 340 1:1), the solution was diluted with CH 2 Cl 2 (4 mL) and water (2 mL). The aqueous layer was extracted with CH 2 Cl 2 (3 Â 4 mL), then the combined organic layers were washed with cold saturated NaHCO 3 solution (1 Â 5 mL), dried (Na 2 SO 4 ) and filtered. The solvent was removed by evaporation under diminished pressure and the residue purified by column chromatography (EtOAc/hexane, 1:2).
Method D: A solution of arylaldehyde (40 mmol), hydroxylamine hydrochloride (80 mmol, 2 equiv) and sodium hydroxide (80 mmol, 2 equiv) in EtOH (50 mL) was stirred at 78°C for 2 h.
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The suspension was filtered and the solid washed with EtOH (2 Â 20 mL). The filtrate was evaporated and the residue dissolved in EtOAc (150 mL). The organic layer was washed with water (3 Â 70 mL), dried (Na 2 SO 4 ), filtered and evaporated to dryness. A portion of the crude arylaldoxime (7 mmol) was then dissolved in DMF (10 mL) and NCS (7 mmol, 1 equiv) was added in 8-10 portions. The reaction was slightly exothermic and NCS portions were added slowly in order to maintain the temperature at 35-40°C. If no heat was generated after the first two additions of NCS, a stream of HCl (generated ex situ from NaCl and H 2 SO 4 ) was bubbled 360 through the solution in order to start the reaction then stopped when the temperature reached 35-40°C. The reaction was then stirred for 3 h at rt and poured into EtOAc (100 mL). The organic layer was washed with water (3 Â 50 mL), dried (Na 2 SO 4 ), filtered and evaporated to dryness. The hydroximoyl chlorides 16b-e,g-k were used for cycloadditions without further purification.
Method E: A solution of glucosyl cyanide 9 (0.5 mmol) and a hydroximoyl chloride (2.5 mmol, 5 equiv) in toluene (5 mL) was stirred at 110°C under argon. Triethylamine (3.75 mmol, 7.5 equiv) was dissolved in toluene (5 mL) and slowly added in 370 12 h with a syringe pump. The reaction was stirred at 110°C for an additional 12 h then the solvent was evaporated under diminished pressure. The residue was purified by flash silica gel column chromatography to afford the desired 1,2,4-oxadiazoles 17.
Method F: A solution of the acyl-protected carbohydrate derivatives 17 (0.15 mmol) and NaOMe (50 lL, 1 M in MeOH) in MeOH (3 mL) was stirred at rt for 3 h. The solution was then neutralized to pH 5 with a cation exchange resin (DOWEX 50WX2, H + form).
The resin was filtered off and washed with MeOH (3 Â 10 mL) then 380 the filtrate was evaporated under diminished pressure. The residue was purified by flash silica gel column chromatography to afford the desired carbohydrate derivatives 8.
Method G: The benzoylated compounds 11 were dissolved in a mixture of abs. MeOH and abs. CHCl 3 and 1 M methanolic sodium methoxide solution was added to the solutions in catalytic amount. The reaction mixture was kept at room temperature for a given time and then neutralized with a cation exchange resin Amberlyst 
2-(4-
Compound 6e (60 mg, 0.17 mmol) was dissolved in a mixture of abs. EtOAc (2 mL) and abs. MeOH (2 mL), and reduced by H 2 (1 atm) using Raney-Ni as catalyst at 60°C for 8 h. After filtration 
5-(b-
D-Glucopyranosyl)-2-(1-naphthyl)-1,
5-(b-D-Glucopyranosyl)-3-(4-hydroxyphenyl)-1,2,4-oxadiazole (8g)
A solution of 17g (173 mg, 0.27 mmol) and NaOMe (5 mg) in MeOH/CH 2 Cl 2 (10 mL, 9:1) was stirred at rt for 24 h. The reaction was neutralized to pH 5-6 with Amberlite IR-120 resin (H + form) and the resin washed with MeOH (3 Â 10 mL). After cooling to rt the mixture was filtered and evaporated. The product 11b was crystallized from EtOH (62 mg, 56%) and obtained as white crystals. Mp = 186-187°C. ½a 
2-(4-Methylphenyl)-5-(2,3,4,6-tetra-O-benzoyl-b-Dglucopyranosyl)-1,3,4-oxadiazole (11c)
To a solution of tetrazole 10 (500 mg, 0.77 mmol) in abs. toluene (5 mL) was added 4-methyl-benzoyl chloride (0.95 mmol). The reaction mixture was refluxed for 3 h then evaporated in vacuum. Crystallisation from EtOH gave 11c (379 mg, 70%) as white crystals. Mp = 170-172°C. ½a 
2-(4-
To a solution of tetrazole 10 (500 mg, 0.77 mmol) in abs. toluene (5 mL) was added 4-methoxy-benzoyl chloride (1.54 mmol). The reaction mixture was refluxed for 1 h. Then it was cooled to rt, washed with saturated aqueous NaHCO 3 solution and water. The organic phase was dried (MgSO 4 ), concentrated under diminished pressure and purified by column chromatography (hexane/ EtOAc, 1:1) to give 11d (235 mg, 40%) as a syrup. ½a 
To a solution of 4-acetoxybenzoic acid (139 mg, 0.77 mmol) and DCC (159 mg, 0.77 mmol) in abs. toluene (5 mL) was added tetra-850 zole 10 (500 mg, 0.77 mmol). The reaction was heated to reflux for 7 h. After cooling to rt the mixture was filtered, evaporated and purified by column chromatography (hexane/EtOAc, 2:1) to give 11l (247 mg, 41%) as a white amorphous product. ½a 
Enzymology
Glycogen phosphorylase b was prepared from rabbit skeletal muscle according to the method of Fischer and Krebs, 42 using dithiothreitol instead of L-cysteine, and recrystallized at least three times before use. Kinetic experiments were performed in the direction of glycogen synthesis as described previously. 43 Kinetic data for the inhibition of rabbit skeletal muscle glycogen phosphorylase 1170 were collected using different concentrations of a-D-glucose-1-phosphate (2-20 mM), constant concentrations of glycogen (1% w/v) and AMP (1 mM), and various concentrations of inhibitors. Inhibitors were dissolved in dimethyl sulfoxide (DMSO) and diluted in the assay buffer (50 mM triethanolamine, 1 mM EDTA and 1 mM dithiothreitol) so that the DMSO concentration in the assay should be lower than 1%. The enzymatic activities were presented in the form of double-reciprocal plots (Lineweaver-Burk) applying a nonlinear data analysis program. The inhibitor constants (K i ) were determined by Dixon plots, by replotting the 1180 slopes from the Lineweaver-Burk plots against the inhibitor concentrations. 17, 44 The means of standard errors for all calculated kinetic parameters averaged to less than 10%.
